Stock Market & Financial Investment News

News Breaks September 25, 2012 09:00 EDT SNTS Santarus momentum likely to continue, says Roth Capital After meeting with Santarus' management, Roth Capital thinks all of the company's programs remain on track, while its Ruconest drug could surpass expectations. The firm maintains a Buy rating on the stock. News For SNTS From The Last 14 Days Check below for free stories on SNTS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 10:36 EDT SNTS Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information May 10, 2013 09:06 EDT SNTS Santarus 4.25M share Spot Secondary priced at $18.25 Subscribe for More Information 09:00 EDT SNTS Santarus falls 7.3% Subscribe for More Information May 9, 2013 16:02 EDT SNTS Santarus files to sell common stock for Cosmo Technologies, no amount given Subscribe for More Information May 7, 2013 09:17 EDT SNTS On The Fly: Pre-market Movers Subscribe for More Information 09:00 EDT SNTS Santarus rises 10.2% Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.